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1. Introduction 
In addition to its antiviral effect, interferon has 
been reported to have biological effects on cell growth 
[ 1,2] and on the immune system [3,4]. DNA synthe- 
sis in mitogen-stimulated lymphocytes was shown to 
be inhibited by interferon [5-71. In human cells, a 
gene on chromosome 21 has been implicated in deter- 
mining the antiviral response to interferon, possibly 
through control over the interferon receptor [8-IO]. 
It was not clear whether chromosome 21 also plays a 
role in the non-viral effects of interferon. It therefore 
seemed of interest to compare the sensitivity to inter- 
feron of lymphoblastogenesis in cells trisomic for 
chromosome 21 (as found in Down’s syndrome) as 
compared to normal (disomic 21) subjects. Incorpora- 
tion of [3H]thymidine in lymphocytes treated with 
mitogens and interferon was used as an in vitro 
measure of cell proliferation resulting from antigen 
stimulation in vivo. 
The results reported indicate that this non-viral 
effect of interferon on lymphoblastogenesis is also 
regulated by genes on chromosome 2 1. The possible 
role of chromosome 2 1 in cell-cell interactions and in 
the immunodeficiency seen in Down’s syndrome is 
discussed. 
2. Materials and methods 
2.1. Interferon 
Human lymphoblastoid interferon was prepared 
Elsevier/North-Holland Biomedical Press 
by Sendai virus induction of Namalva cells [ 111. 
After inactivation of virus by pH 2 treatment, the 
crude interferon was partially purified by antibody 
affinity chromatography [ 12 1. Human fibroblast 
interferon was prepared by super-induction of fore- 
skin fibroblasts [ 131. 
2.2. Lymphocytes 
Blood was obtained from non-institutionalized 
children suffering from Down’s syndrome (age, 3 
months-8 years) and from normal age-matched con- 
trols. Karyotyping was carried out on all Down’s 
syndrome subjects and all were found to be trisomic 
in chromosome 21. Lymphocytes were prepared by 
density gradient centrifugation on lymphoprep 
(Nyegaard and Co., A/S, Oslo) by the method in 1141 
using heparinised blood diluted in Dulbecco modified 
phosphate buffered saline (PBS). The lymphocytes 
were washed 3 times in PBS (250 X g, 10 min) and 
resuspended in RPM1 1640 medium (Gibco) supple- 
mented with penicillin (100 units/ml), streptomycin 
(100 fig/ml) and 5% fetal calf serum (Gibco). Fetal 
calf serum was heat-inactivated (56’C, 30 min) before 
use. 
Incubation of lymphocytes was carried out in trip- 
licate in microtiter plates (Falcon, 3041/2) using 
6-10 X IO4 cells/O.2 ml/well. Mitogens used were 
phytohemagglutinin (PHA-P; Difco, MI), concanavalin 
A (con A; Miles Yeda) and pokeweed mitogen (PWM; 
Gibco, NY). The mitogen concentrations which gave 
optimal stimulation of lymphocytes were PHA 20 pg/ml, 
and con A and PWM 5 pg/ml. The incubation was 
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carried out at 37”C, in a humidified atmosphere of 
5% C02-95% air. Interferon was used at O-1600 
units/ml. Both mitogen and interferon were added at 
the start of the 6.5 h incubation. At the end of this 
time a 4 h pulse of 1 &i [3H] thymidine (Israel AEC, 
Negev; lo-20 Ci/mmol) was given. Cells were then 
harvested (MASH II harvester Microbiological Associ- 
ates) on glass fibre filters (Whatman GFC) and washed 
prior to scintillation counting (Bray’s scintillation 
fluid) in a liquid scintillation spectrometer (Packard). 
3. Results 
3.1. Stimulation of [ 3H]thymidine incorporation by 
mitogens 
Table 1 shows the results of mitogen stimulation 
of lymphocytes derived from Down’s syndrome and 
from normal subjects, in a series of experiments. As 
I I I I 
PHA 
Fig.la 
Table 1 
[3H]Thymidine uptake (cpm X 10e3) 
Control PHA con A PWM 
Normal 0.4 -2.0 46-136 46-76 10 -32 
Down’s 0.80-1.6 33-130 37-82 0.6-14 
r3H]Thymidine incorporation in lymphocytes as a result of 
mitogen stimulation. Conditions are in section 2, with 100 000 
cells/well. Figures given are the range of counts determined in 
14 Down’s syndrome subjects and 12 controls. For details see 
section 3 
can be seen, both PHA and con A elicit in Down’s- 
derived lymphocytes reactions which are comparable 
to those obtained with normal cells. In the case of 
PWM, the stimulation observed in Down&derived 
lymphocytes was significantly lower than that in 
normal cells. The figures given are the range of counts 
I I I I 
I I I I 
0 loo 200 300 400 
Fig.lb Interferon , umtr/ml 
Fig.1. Effect of interferon on [3H]thymidine incorporation into normal (0) and Down’s syndrome (0) lymphocytes on stimula. 
tion with mitogens. Lymphocytes were prepared on a lymphoprep gradient and after washing were resuspended in RPM1 1640 
medium containing 5% fetal calf serum. Cells were incubated at 100 000 cells/O.2 ml in the presence or absence of mitogen (PHA. 
50 pg/ml, fig.la; con A. 5 pg/ml, fig.lb) and of interferon at concentrations shown. After 65 h incubation, a 4 h pulse of [ ‘HI- 
thymidine (1 MCi) was given. [ ‘H]Thymidine incorporated into the cells was determined by scintillation counting of the harvested 
and washed cells. 
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determined in 14 Down’s syndrome subjects and 12 
controls, which showed good stimulation with mitogens. 
The stimulation conditions used in these experiments, 
see section 2, were found to be optimal conditions 
for both normal and Down’s_derived lymphocytes. 
Indeed, a series of experiments with varying mitogen 
concentrations (PHA 2-40 pg/ml; con A 0.5-l 0 pg/ml; 
PWM OS-10 pg/ml) and variation of incubation time 
with mitogen (48-96 h), indicated that Down’s syn- 
drome and normal lymphocytes are optimally stimu- 
lated under the same conditions. 
3.2. Effect of interferon on mitogen stimulation 
The effect of partially purified lymphoblastoid 
interferon on con A- or PHA-stimulation of [jH]- 
thymidine incorporation is shown in fig.1. Interferon 
decreased [3H]thymidine incorporation into DNA in 
normal and in Down’s syndrome lymphocytes stimu- 
lated by either mitogen. With con A-stimulated 
lymphocytes, the concentration of interferon needed 
to produce a 5% inhibition was about 4-fold less in 
Down’s syndrome lymphocytes trisomic in chromo- 
some 21, than in normal diploid lymphocytes. In 
PHA-stimulated cells, the extent of inhibition by 
interferon in Down’s lymphocytes was also greater 
than that observed in normal cells. The PHA-induced 
response in normal cells was not markedly inhibited, 
whereas the stimulation in trisomic cells was signifi- 
cantly inhibited by interferon. 
Experiments performed with human fibroblast 
interferon (results not shown) gave similar results to 
those described, which were carried out with lympho- 
blastoid interferon. 
4. Discussion 
The involvement of chromose 21 in determining 
cell sensitivity to the antiviral effect of interferon in 
humans has been reported [7,15-171. We were therefore 
interested in investigating the effect of interferon on 
another non-antiviral function in the chromosome 2 1 
associated Down’s syndrome. 
The property of interferon in inhibiting cell prolif- 
eration has now been shown to reside in the same 
molecule which inhibits virus growth [ 1,181. A conve- 
nient system for study of the anti-proliferative effects 
of interferon is mitogen-induced DNA synthesis in 
human peripheral blood lymphoid cells. This effect of 
interferon on DNA replication may be closely related 
to its anti-tumor effect. 
The results reported indicate that trisomy in chro- 
mosome 21 causes no significant alteration in the re- 
sponse of lymphocytes to the two T-cell mitogens 
studied, PHA and con A, in [‘Hlthymidine uptake. 
Both decreased and increased lymphocyte response in 
PHA have been reported [19-211. It is also clear that 
Down’s syndrome lymphocytes are significantly more 
sensitive to interferon than normal lymphocytes in 
both the PHA- and con A-induced response. Similar 
results concerning the effect of interferon on PHA- 
induced lymphoblastogenesis in Down’s syndrome are 
in [22]. 
While interferon significantly suppresses the [jH]- 
thymidine response to con A, there is a less-marked 
inhibition of the PHA-induced effect. This is of par- 
ticular interest since data from several aboratories 
working on both human and murine systems indicate 
that there are different subsets of the Tcell popula- 
tion which differ in their response to PHA and to 
con A [23]. These populations have been shown to 
differ not only in their ontogeny but also in their 
involvement in different T-cell functions in mammals 
[24]. Thus, it has been demonstrated that the Ly 1’ 
T-cell subpopulation, a high PHA responder, is mainly 
involved in providing obligatory antigen-specific help 
to B-cells. In addition, this is the main subpopulation 
capable of responding strongly to alloantigens associ- 
ated with major histocompatibility systems. On the 
other hand, the Ly 2’ T-cell subpopulation which 
responds strongly to con A, is mainly involved in the 
generation of suppressor T-cells and anti-self-modified 
killer cells. The latter are of prime importance in 
enabling animals to eliminate virus-infected cells [24]. 
These data may therefore indicate a differential regu- 
latory role of interferon in regulation of the function 
of different T-cell subpopulations. 
Based on data indicating that chromosome 21 
codes for a cell surface component [8], the greater 
sensitivity to interferon of lymphoid cells with trisomic 
chromosome 21 may be due to the presence of a larger 
number of receptors for interferon on these cells. 
Alternatively, the increased sensitivity may be due to 
a change in membrane characteristics. The possible 
involvement of chromosome 2 1 in such membrane 
alterations is highly relevant in view of the known 
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anatomic abnormalities found in Down’s syndrome 
which could well stem from defects in cell-cell inter- 
action during embryogenesis. This hypothesis gains 
support from the fact that in contrast to the relatively 
normal response of Down’s syndrome lymphocytes to 
T-cell mitogens, we found a severely impaired response 
to pokeweed mitogen which is a B-cell mitogen 
requiring T-cell cooperation [25]. This decreased 
stimulation by pokeweed mitogen was not due to 
alterations in the optimal conditions for stimulation 
of Down’s cells by the mitogen since the same effect 
was demonstrated over a wide range of mitogen con- 
centrations and at various times after mitogen addi- 
tion. 
It may be pertinent to focus attention on the 
abnormalities accompanying Down’s syndrome, as 
compared to those found in murine cells with abnor- 
malities in chromosome 17 (T-locus mutants) [26]. It 
is possible that the T-locus-associated genes on chro- 
mosome 17 in mice correspond to some of those 
found in chromosome 21 in man. 
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